AR and prostate cancer: By integrating expression profile data from clinical tissues with chromatin immunoprecipitation sequencing (ChIP-seq) data of AR-binding sites (ARBSs) in androgen-responsive prostate cancer LNCaP cells, five miRNAs, miR-32, miR-148a, miR-99a, miR-21, and miR-221, showed differential expressions in CRPC samples and in the presence of ARBSs upstream, with no other genes nearby [77].